Abstract
The protein molecules must fold into unique conformations to acquire functional activity. Misfolding, aggregation, and deposition of proteins in diverse organs, the so-called “protein misfolding disorders (PMDs)”, represent the conformational diseases with highly ordered assemblies, including oligomers and fibrils that are linked to neurodegeneration in brain illnesses such as cerebral amyloid angiopathy (CAA) and Alzheimer’s disease (AD). Recent studies have revealed several aspects of brain pathology in CAA and AD, but both the classification and underlying mechanisms need to be further refined. MicroRNAs (miRNAs) are critical regulators of gene expression at the post-transcriptional level. Increasing evidence with the advent of RNA sequencing technology suggests possible links between miRNAs and these neurodegenerative disorders. To provide insights on the small RNA-mediated regulatory circuitry and the translational significance of miRNAs in PMDs, this review will discuss the characteristics and mechanisms of the diseases and summarize circulating or tissue-resident miRNAs associated with AD and CAA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Absalon, S., Kochanek, D. M., Raghavan, V., & Krichevsky, A. M. (2013). MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. Journal of Neuroscience,33(37), 14645–14659. https://doi.org/10.1523/JNEUROSCI.1327-13.2013.
Adams, S. J., Crook, R. J., Deture, M., Randle, S. J., Innes, A. E., Yu, X. Z., et al. (2009). Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. American Journal of Pathology,175(4), 1598–1609. https://doi.org/10.2353/ajpath.2009.090462.
Akter, R., Cao, P., Noor, H., Ridgway, Z., Tu, L. H., Wang, H., et al. (2016). Islet amyloid polypeptide: Structure, function, and pathophysiology. Journal of Diabetes Research,2016, 2798269. https://doi.org/10.1155/2016/2798269.
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement,7(3), 270–279. https://doi.org/10.1016/j.jalz.2011.03.008.
Alexandrov, P. N., Dua, P., Hill, J. M., Bhattacharjee, S., Zhao, Y., & Lukiw, W. J. (2012). microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). International Journal of Biochemistry and Molecular Biology,3(4), 365–373.
Ameres, S. L., & Zamore, P. D. (2013). Diversifying microRNA sequence and function. Nature Reviews Molecular Cell Biology,14(8), 475–488. https://doi.org/10.1038/nrm3611.
Andersen, P. M., & Al-Chalabi, A. (2011). Clinical genetics of amyotrophic lateral sclerosis: What do we really know? Nature Reviews Neurology,7(11), 603–615. https://doi.org/10.1038/nrneurol.2011.150.
Association, A. s. (2019). Alzheimer’s disease facts and figures. Alzheimers Dement 15(3):321-387.
Auriel, E., & Greenberg, S. M. (2012). The pathophysiology and clinical presentation of cerebral amyloid angiopathy. Current Atherosclerosis Reports,14(4), 343–350. https://doi.org/10.1007/s11883-012-0254-z.
Backman, L., Jones, S., Berger, A. K., Laukka, E. J., & Small, B. J. (2004). Multiple cognitive deficits during the transition to Alzheimer’s disease. Journal of Internal Medicine,256(3), 195–204. https://doi.org/10.1111/j.1365-2796.2004.01386.x.
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011). Alzheimer’s disease. Lancet,377(9770), 1019–1031. https://doi.org/10.1016/S0140-6736(10)61349-9.
Ballatore, C., Lee, V. M., & Trojanowski, J. Q. (2007). Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nature Reviews Neuroscience,8(9), 663–672. https://doi.org/10.1038/nrn2194.
Banzhaf-Strathmann, J., Benito, E., May, S., Arzberger, T., Tahirovic, S., Kretzschmar, H., et al. (2014). MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. EMBO Journal,33(15), 1667–1680. https://doi.org/10.15252/embj.201387576.
Banzhaf-Strathmann, J., & Edbauer, D. (2014). Good guy or bad guy: The opposing roles of microRNA 125b in cancer. Cell Communication and Signaling,12, 30. https://doi.org/10.1186/1478-811X-12-30.
Barry, G. (2014). Integrating the roles of long and small non-coding RNA in brain function and disease. Molecular Psychiatry,19(4), 410–416. https://doi.org/10.1038/mp.2013.196.
Bartel, D. P. (2009). MicroRNAs: Target recognition and regulatory functions. Cell,136(2), 215–233. https://doi.org/10.1016/j.cell.2009.01.002.
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., et al. (2011). Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimers Research & Therapy,3(1), 1. https://doi.org/10.1186/alzrt59.
Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. New England Journal of Medicine,367(9), 795–804. https://doi.org/10.1056/NEJMoa1202753.
Bekris, L. M., Lutz, F., Montine, T. J., Yu, C. E., Tsuang, D., Peskind, E. R., et al. (2013). MicroRNA in Alzheimer’s disease: An exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers,18(5), 455–466. https://doi.org/10.3109/1354750X.2013.814073.
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., et al. (2006). Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology,66(12), 1837–1844. https://doi.org/10.1212/01.wnl.0000219668.47116.e6.
Bhatnagar, S., Chertkow, H., Schipper, H. M., Yuan, Z., Shetty, V., Jenkins, S., et al. (2014). Increased microRNA-34c abundance in Alzheimer’s disease circulating blood plasma. Frontiers in Molecular Neuroscience,7, 2. https://doi.org/10.3389/fnmol.2014.00002.
Biffi, A., & Greenberg, S. M. (2011). Cerebral amyloid angiopathy: A systematic review. Journal of Clinical Neurology,7(1), 1–9. https://doi.org/10.3988/jcn.2011.7.1.1.
Blennow, K., Mattsson, N., Scholl, M., Hansson, O., & Zetterberg, H. (2015). Amyloid biomarkers in Alzheimer’s disease. Trends in Pharmacological Sciences,36(5), 297–309. https://doi.org/10.1016/j.tips.2015.03.002.
Bohm, C., Chen, F., Sevalle, J., Qamar, S., Dodd, R., Li, Y., et al. (2015). Current and future implications of basic and translational research on amyloid-beta peptide production and removal pathways. Molecular and Cellular Neuroscience,66(Pt A), 3–11. https://doi.org/10.1016/j.mcn.2015.02.016.
Borroni, B., Di Luca, M., & Padovani, A. (2006). Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful? European Journal of Pharmacology,545(1), 73–80. https://doi.org/10.1016/j.ejphar.2006.06.023.
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., et al. (2016). Tau and Abeta imaging, CSF measures, and cognition in Alzheimer’s disease. Science Translational Medicine,8(338), 338ra366. https://doi.org/10.1126/scitranslmed.aaf2362.
Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., et al. (2006). CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain,129(Pt 11), 3035–3041. https://doi.org/10.1093/brain/awl269.
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., et al. (2014). Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer’s and Parkinson’s diseases correlate with disease status and features of pathology. PLoS ONE,9(5), e94839. https://doi.org/10.1371/journal.pone.0094839.
Caughey, B., & Lansbury, P. T. (2003). Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annual Review of Neuroscience,26, 267–298. https://doi.org/10.1146/annurev.neuro.26.010302.081142.
Chabrier, M. A., Blurton-Jones, M., Agazaryan, A. A., Nerhus, J. L., Martinez-Coria, H., & LaFerla, F. M. (2012). Soluble Abeta promotes wild-type tau pathology in vivo. Journal of Neuroscience,32(48), 17345–17350. https://doi.org/10.1523/JNEUROSCI.0172-12.2012.
Charidimou, A., Boulouis, G., Gurol, M. E., Ayata, C., Bacskai, B. J., Frosch, M. P., et al. (2017). Emerging concepts in sporadic cerebral amyloid angiopathy. Brain,140(7), 1829–1850. https://doi.org/10.1093/brain/awx047.
Chase, W. R. (1992). You gave me back my life. Journal of the Michigan Dental Association,74(7), 28–30.
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., et al. (2008). Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research,18(10), 997–1006. https://doi.org/10.1038/cr.2008.282.
Cheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., et al. (2015). Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Molecular Psychiatry,20(10), 1188–1196. https://doi.org/10.1038/mp.2014.127.
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M. Y., et al. (2013). Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. Journal of Alzheimers Disease,34(2), 457–468. https://doi.org/10.3233/JAD-122059.
Chiti, F., & Dobson, C. M. (2017). Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. Annual Review of Biochemistry,86, 27–68. https://doi.org/10.1146/annurev-biochem-061516-045115.
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., et al. (2008). Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. Journal of Alzheimers Disease,14(1), 27–41.
Cosin-Tomas, M., Antonell, A., Llado, A., Alcolea, D., Fortea, J., Ezquerra, M., et al. (2017). Plasma miR-34a-5p and miR-545-3p as early biomarkers of alzheimer’s disease: Potential and limitations. Molecular Neurobiology,54(7), 5550–5562. https://doi.org/10.1007/s12035-016-0088-8.
Davidson, Y. S., Robinson, A., Prasher, V. P., & Mann, D. M. A. (2018). The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer’s disease in individuals with Down syndrome. Acta Neuropathologica Communications,6(1), 56. https://doi.org/10.1186/s40478-018-0559-4.
Davis, J., Xu, F., Hatfield, J., Lee, H., Hoos, M. D., Popescu, D., et al. (2018). A novel transgenic rat model of robust cerebral microvascular amyloid with prominent vasculopathy. American Journal of Pathology,188(12), 2877–2889. https://doi.org/10.1016/j.ajpath.2018.07.030.
Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015). MicroRNA profiling of CSF reveals potential biomarkers to detect Alzheimer`s disease. PLoS ONE,10(5), e0126423. https://doi.org/10.1371/journal.pone.0126423.
Dobson, C. M. (1999). Protein misfolding, evolution and disease. Trends in Biochemical Sciences,24(9), 329–332.
Dong, H., Li, J., Huang, L., Chen, X., Li, D., Wang, T., et al. (2015). Serum MicroRNA profiles serve as novel biomarkers for the diagnosis of alzheimer’s disease. Disease Markers,2015, 625659. https://doi.org/10.1155/2015/625659.
Donohue, M. C., Jacqmin-Gadda, H., Le Goff, M., Thomas, R. G., Raman, R., Gamst, A. C., et al. (2014). Estimating long-term multivariate progression from short-term data. Alzheimers Dement,10(5 Suppl), S400–S410. https://doi.org/10.1016/j.jalz.2013.10.003.
Du, X., Huo, X., Yang, Y., Hu, Z., Botchway, B. O. A., Jiang, Y., et al. (2017). miR-124 downregulates BACE 1 and alters autophagy in APP/PS1 transgenic mice. Toxicology Letters,280, 195–205. https://doi.org/10.1016/j.toxlet.2017.08.082.
Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010). Transgenic mouse models of Alzheimer’s disease. Mount Sinai Journal of Medicine,77(1), 69–81. https://doi.org/10.1002/msj.20159.
Filipowicz, W., Bhattacharyya, S. N., & Sonenberg, N. (2008). Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nature Reviews Genetics,9(2), 102–114. https://doi.org/10.1038/nrg2290.
Fink, A. L. (1998). Protein aggregation: Folding aggregates, inclusion bodies and amyloid. Folding and Design,3(1), R9–R23. https://doi.org/10.1016/S1359-0278(98)00002-9.
Fleisher, A. S., Chen, K., Liu, X., Roontiva, A., Thiyyagura, P., Ayutyanont, N., et al. (2011). Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Archives of Neurology,68(11), 1404–1411. https://doi.org/10.1001/archneurol.2011.150.
Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gutierrez Gomez, M., Langois, C. M., et al. (2015). Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurology,72(3), 316–324. https://doi.org/10.1001/jamaneurol.2014.3314.
Forstl, H., & Kurz, A. (1999). Clinical features of Alzheimer’s disease. European Archives of Psychiatry and Clinical Neuroscience,249(6), 288–290.
Galimberti, D., Villa, C., Fenoglio, C., Serpente, M., Ghezzi, L., Cioffi, S. M., et al. (2014). Circulating miRNAs as potential biomarkers in Alzheimer’s disease. Journal of Alzheimers Disease,42(4), 1261–1267. https://doi.org/10.3233/JAD-140756.
Gantier, M. P., McCoy, C. E., Rusinova, I., Saulep, D., Wang, D., Xu, D., et al. (2011). Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Research,39(13), 5692–5703. https://doi.org/10.1093/nar/gkr148.
Geekiyanage, H., Jicha, G. A., Nelson, P. T., & Chan, C. (2012). Blood serum miRNA: Non-invasive biomarkers for Alzheimer’s disease. Experimental Neurology,235(2), 491–496. https://doi.org/10.1016/j.expneurol.2011.11.026.
Giraldez, A. J., Cinalli, R. M., Glasner, M. E., Enright, A. J., Thomson, J. M., Baskerville, S., et al. (2005). MicroRNAs regulate brain morphogenesis in zebrafish. Science,308(5723), 833–838. https://doi.org/10.1126/science.1109020.
Glabe, C. G. (2006). Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiology of Aging,27(4), 570–575. https://doi.org/10.1016/j.neurobiolaging.2005.04.017.
Goodall, E. F., Heath, P. R., Bandmann, O., Kirby, J., & Shaw, P. J. (2013). Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Frontiers in Cellular Neuroscience,7, 178. https://doi.org/10.3389/fncel.2013.00178.
Grasso, M., Piscopo, P., Confaloni, A., & Denti, M. A. (2014). Circulating miRNAs as biomarkers for neurodegenerative disorders. Molecules,19(5), 6891–6910. https://doi.org/10.3390/molecules19056891.
Greenberg, S. M., & Charidimou, A. (2018). Diagnosis of cerebral amyloid angiopathy: Evolution of the Boston criteria. Stroke,49(2), 491–497. https://doi.org/10.1161/STROKEAHA.117.016990.
Gui, Y., Liu, H., Zhang, L., Lv, W., & Hu, X. (2015). Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget,6(35), 37043–37053. https://doi.org/10.18632/oncotarget.6158.
Hammond, S. M. (2015). An overview of microRNAs. Advanced Drug Delivery Reviews,87, 3–14. https://doi.org/10.1016/j.addr.2015.05.001.
Hardy, J. (2006). Has the amyloid cascade hypothesis for Alzheimer’s disease been proved? Current Alzheimer Research,3(1), 71–73.
Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science,297(5580), 353–356. https://doi.org/10.1126/science.1072994.
He, D., Tan, J., & Zhang, J. (2017). miR-137 attenuates Abeta-induced neurotoxicity through inactivation of NF-kappaB pathway by targeting TNFAIP1 in Neuro2a cells. Biochemical and Biophysical Research Communications,490(3), 941–947. https://doi.org/10.1016/j.bbrc.2017.06.144.
Hebert, S. S., Horre, K., Nicolai, L., Bergmans, B., Papadopoulou, A. S., Delacourte, A., et al. (2009). MicroRNA regulation of Alzheimer’s Amyloid precursor protein expression. Neurobiology of Diseases,33(3), 422–428. https://doi.org/10.1016/j.nbd.2008.11.009.
Hebert, S. S., Horre, K., Nicolai, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., et al. (2008). Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proceedings of the National Academy of Sciences,105(17), 6415–6420. https://doi.org/10.1073/pnas.0710263105.
Hebert, S. S., Papadopoulou, A. S., Smith, P., Galas, M. C., Planel, E., Silahtaroglu, A. N., et al. (2010). Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Human Molecular Genetics,19(20), 3959–3969. https://doi.org/10.1093/hmg/ddq311.
Helwak, A., Kudla, G., Dudnakova, T., & Tollervey, D. (2013). Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell,153(3), 654–665. https://doi.org/10.1016/j.cell.2013.03.043.
Hernandez-Rapp, J., Rainone, S., Goupil, C., Dorval, V., Smith, P. Y., Saint-Pierre, M., et al. (2016). microRNA-132/212 deficiency enhances Abeta production and senile plaque deposition in Alzheimer’s disease triple transgenic mice. Scientific Reports,6, 30953. https://doi.org/10.1038/srep30953.
Herzig, M. C., Winkler, D. T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S. D., et al. (2004). Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nature Neuroscience,7(9), 954–960. https://doi.org/10.1038/nn1302.
Higaki, S., Muramatsu, M., Matsuda, A., Matsumoto, K., Satoh, J. I., Michikawa, M., et al. (2018). Defensive effect of microRNA-200b/c against amyloid-beta peptide-induced toxicity in Alzheimer’s disease models. PLoS ONE,13(5), e0196929. https://doi.org/10.1371/journal.pone.0196929.
Hong, H., Li, Y., & Su, B. (2017). Identification of circulating miR-125b as a potential biomarker of Alzheimer’s disease in APP/PS1 transgenic mouse. Journal of Alzheimer’s Disease,59(4), 1449–1458. https://doi.org/10.3233/JAD-170156.
Howe, M. D., Atadja, L. A., Furr, J. W., Maniskas, M. E., Zhu, L., McCullough, L. D., et al. (2018a). Fibronectin induces the perivascular deposition of cerebrospinal fluid-derived amyloid-beta in aging and after stroke. Neurobiology of Aging,72, 1–13. https://doi.org/10.1016/j.neurobiolaging.2018.07.019.
Howe, M. D., Zhu, L., Sansing, L. H., Gonzales, N. R., McCullough, L. D., & Edwards, N. J. (2018b). Serum markers of blood-brain barrier remodeling and fibrosis as predictors of etiology and clinicoradiologic outcome in intracerebral hemorrhage. Frontiers in Neurology,9, 746. https://doi.org/10.3389/fneur.2018.00746.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., et al. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science,274(5284), 99–102.
Hsu, P. W., Huang, H. D., Hsu, S. D., Lin, L. Z., Tsou, A. P., Tseng, C. P., et al. (2006). miRNA Map: Genomic maps of microRNA genes and their target genes in mammalian genomes. Nucleic Acids Research 34(Database issue), D135-139, https://doi.org/10.1093/nar/gkj135.
Hu, S., Wang, H., Chen, K., Cheng, P., Gao, S., Liu, J., et al. (2015). MicroRNA-34c downregulation ameliorates amyloid-beta-induced synaptic failure and memory deficits by targeting VAMP2. Journal of Alzheimers Disease,48(3), 673–686. https://doi.org/10.3233/JAD-150432.
Huang, Y., Shen, X. J., Zou, Q., Wang, S. P., Tang, S. M., & Zhang, G. Z. (2011). Biological functions of microRNAs: A review. Journal of Physiology and Biochemistry,67(1), 129–139. https://doi.org/10.1007/s13105-010-0050-6.
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., et al. (2008). Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain,131(Pt 6), 1630–1645. https://doi.org/10.1093/brain/awn016.
Iqbal, K., & Grundke-Iqbal, I. (2010). Alzheimer’s disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement,6(5), 420–424. https://doi.org/10.1016/j.jalz.2010.04.006.
Jack, C. R., Jr., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., et al. (2011). Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement,7(3), 257–262. https://doi.org/10.1016/j.jalz.2011.03.004.
Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., et al. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement,14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018.
Jack, C. R., Jr., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., et al. (2008). 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain,131(Pt 3), 665–680. https://doi.org/10.1093/brain/awm336.
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., et al. (2004). Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Human Molecular Genetics,13(2), 159–170. https://doi.org/10.1093/hmg/ddh019.
Jankowsky, J. L., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., & Borchelt, D. R. (2001). Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomolecular Engineering,17(6), 157–165.
Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., & Wirths, O. (2012). Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer’s disease. Neurobiology of Aging,33(1), 196.e29–196.e140. https://doi.org/10.1016/j.neurobiolaging.2010.05.027.
Jiang, Y., Xu, B., Chen, J., Sui, Y., Ren, L., Li, J., et al. (2018). Micro-RNA-137 inhibits Tau hyperphosphorylation in Alzheimer’s disease and targets the CACNA1C gene in transgenic mice and human neuroblastoma SH-SY5Y cells. Medical Science Monitor,24, 5635–5644. https://doi.org/10.12659/MSM.908765.
Johnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., et al. (2013). Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement,9(5 Suppl), S72–S83. https://doi.org/10.1016/j.jalz.2012.10.007.
Kayano, M., Higaki, S., Satoh, J. I., Matsumoto, K., Matsubara, E., Takikawa, O., et al. (2016). Plasma microRNA biomarker detection for mild cognitive impairment using differential correlation analysis. Biomarker Research,4, 22. https://doi.org/10.1186/s40364-016-0076-1.
Kiko, T., Nakagawa, K., Tsuduki, T., Furukawa, K., Arai, H., & Miyazawa, T. (2014). MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. Journal of Alzheimers Disease,39(2), 253–259. https://doi.org/10.3233/JAD-130932.
Knopman, D. S., Haeberlein, S. B., Carrillo, M. C., Hendrix, J. A., Kerchner, G., Margolin, R., et al. (2018). The National Institute on Aging and the Alzheimer’s Association Research framework for Alzheimer’s disease: Perspectives from the research roundtable. Alzheimers Dement,14(4), 563–575. https://doi.org/10.1016/j.jalz.2018.03.002.
Knopman, D. S., Jack, C. R., Jr., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., et al. (2013). Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Annals of Neurology,73(4), 472–480. https://doi.org/10.1002/ana.23816.
Knudsen, K. A., Rosand, J., Karluk, D., & Greenberg, S. M. (2001). Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston criteria. Neurology,56(4), 537–539.
Kosik, K. S., & Krichevsky, A. M. (2005). The elegance of the MicroRNAs: A neuronal perspective. Neuron,47(6), 779–782. https://doi.org/10.1016/j.neuron.2005.08.019.
Kumar, S., Reddy, A. P., Yin, X., & Reddy, P. H. (2019). Novel MicroRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer’s disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease,1865(9), 2428–2440. https://doi.org/10.1016/j.bbadis.2019.06.006.
Kumar, S., Vijayan, M., & Reddy, P. H. (2017). MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease. Human Molecular Genetics,26(19), 3808–3822. https://doi.org/10.1093/hmg/ddx267.
Lee, K., Kim, H., An, K., Kwon, O. B., Park, S., Cha, J. H., et al. (2016). Replenishment of microRNA-188-5p restores the synaptic and cognitive deficits in 5XFAD mouse model of Alzheimer’s disease. Scientific Reports,6, 34433. https://doi.org/10.1038/srep34433.
Lei, X., Lei, L., Zhang, Z., Zhang, Z., & Cheng, Y. (2015). Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer’s disease. International Journal of Clinical and Experimental Pathology,8(2), 1565–1574.
Leidinger, P., Backes, C., Deutscher, S., Schmitt, K., Mueller, S. C., Frese, K., et al. (2013). A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biology,14(7), R78. https://doi.org/10.1186/gb-2013-14-7-r78.
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996). Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiology of Diseases,3(1), 16–32. https://doi.org/10.1006/nbdi.1996.0003.
Lennox, K. A., & Behlke, M. A. (2010). A direct comparison of anti-microRNA oligonucleotide potency. Pharmaceutical Research,27(9), 1788–1799. https://doi.org/10.1007/s11095-010-0156-0.
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell,120(1), 15–20. https://doi.org/10.1016/j.cell.2004.12.035.
Li, H. H., Lin, S. L., Huang, C. N., Lu, F. J., Chiu, P. Y., Huang, W. N., et al. (2016). miR-302 Attenuates Amyloid-beta-Induced Neurotoxicity through Activation of Akt Signaling. Journal of Alzheimers Disease,50(4), 1083–1098. https://doi.org/10.3233/JAD-150741.
Li, J., & Wang, H. (2018). miR-15b reduces amyloid-beta accumulation in SH-SY5Y cell line through targeting NF-kappaB signaling and BACE1. Bioscience Reports. https://doi.org/10.1042/BSR20180051.
Liang, C., Zhu, H., Xu, Y., Huang, L., Ma, C., Deng, W., et al. (2012). MicroRNA-153 negatively regulates the expression of amyloid precursor protein and amyloid precursor-like protein 2. Brain Research,1455, 103–113. https://doi.org/10.1016/j.brainres.2011.10.051.
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., et al. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature,433(7027), 769–773. https://doi.org/10.1038/nature03315.
Liu, W., Liu, C., Zhu, J., Shu, P., Yin, B., Gong, Y., et al. (2012). MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer’s-associated pathogenesis in SAMP8 mice. Neurobiology of Aging,33(3), 522–534. https://doi.org/10.1016/j.neurobiolaging.2010.04.034.
Liu, C. G., Wang, J. L., Li, L., & Wang, P. C. (2014a). MicroRNA-384 regulates both amyloid precursor protein and beta-secretase expression and is a potential biomarker for Alzheimer’s disease. International Journal of Molecular Medicine,34(1), 160–166. https://doi.org/10.3892/ijmm.2014.1780.
Liu, C. G., Wang, J. L., Li, L., Xue, L. X., Zhang, Y. Q., & Wang, P. C. (2014b). MicroRNA-135a and -200b, potential biomarkers for Alzheimers disease, regulate beta secretase and amyloid precursor protein. Brain Research,1583, 55–64. https://doi.org/10.1016/j.brainres.2014.04.026.
Liu, C. D., Wang, Q., Zong, D. K., Pei, S. C., Yan, Y., Yan, M. L., et al. (2016a). Knockdown of microRNA-195 contributes to protein phosphatase-2A inactivation in rats with chronic brain hypoperfusion. Neurobiology of Aging,45, 76–87. https://doi.org/10.1016/j.neurobiolaging.2016.05.010.
Liu, W., Zhao, J., & Lu, G. (2016b). miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer’s disease. Biochemical and Biophysical Research Communications,478(2), 852–857. https://doi.org/10.1016/j.bbrc.2016.08.037.
Londin, E., Loher, P., Telonis, A. G., Quann, K., Clark, P., Jing, Y., et al. (2015). Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences USA,112(10), E1106–E1115. https://doi.org/10.1073/pnas.1420955112.
Long, J. M., Ray, B., & Lahiri, D. K. (2012). MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. Journal of Biological Chemistry,287(37), 31298–31310. https://doi.org/10.1074/jbc.M112.366336.
Lukiw, W. J. (2007). Micro-RNA speciation in fetal, adult and Alzheimer’s disease hippocampus. NeuroReport,18(3), 297–300. https://doi.org/10.1097/WNR.0b013e3280148e8b.
Lukiw, W. J., Zhao, Y., & Cui, J. G. (2008). An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. Journal of Biological Chemistry,283(46), 31315–31322. https://doi.org/10.1074/jbc.M805371200.
Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., et al. (2018). Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Diseases,4, 21. https://doi.org/10.1038/s41531-018-0058-0.
Martin, I., Dawson, V. L., & Dawson, T. M. (2011). Recent advances in the genetics of Parkinson’s disease. Annual Review of Genomics and Human Genetics,12, 301–325. https://doi.org/10.1146/annurev-genom-082410-101440.
Martinez, B., & Peplow, P. V. (2019). MicroRNAs as diagnostic and therapeutic tools for Alzheimer’s disease: Advances and limitations. Neural Regeneration Research,14(2), 242–255. https://doi.org/10.4103/1673-5374.244784.
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Jr., Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement,7(3), 263–269. https://doi.org/10.1016/j.jalz.2011.03.005.
Mead, S., & Reilly, M. M. (2015). A new prion disease: Relationship with central and peripheral amyloidoses. Nature Reviews Neurology,11(2), 90–97. https://doi.org/10.1038/nrneurol.2014.263.
Millan, M. J. (2017). Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: An integrative review. Progress in Neurobiology,156, 1–68. https://doi.org/10.1016/j.pneurobio.2017.03.004.
Mintun, M. A., Larossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., et al. (2006). [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology,67(3), 446–452. https://doi.org/10.1212/01.wnl.0000228230.26044.a4.
Miya Shaik, M., Tamargo, I. A., Abubakar, M. B., Kamal, M. A., Greig, N. H., & Gan, S. H. (2018). The role of microRNAs in Alzheimer’s disease and their therapeutic potentials. Genes (Basel). https://doi.org/10.3390/genes9040174.
Mohr, A. M., & Mott, J. L. (2015). Overview of microRNA biology. Seminars in Liver Disease,35(1), 3–11. https://doi.org/10.1055/s-0034-1397344.
Moreno-Gonzalez, I., & Soto, C. (2011). Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Seminars in Cell & Developmental Biology,22(5), 482–487. https://doi.org/10.1016/j.semcdb.2011.04.002.
Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Amariglio, R. E., Rentz, D. M., et al. (2014). Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurology,71(11), 1379–1385. https://doi.org/10.1001/jamaneurol.2014.2031.
Morris, J. C., & Cummings, J. (2005). Mild cognitive impairment (MCI) represents early-stage Alzheimer’s disease. Journal of Alzheimers Disease,7(3), 235–239. discussion 255-262.
Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., et al. (2001). Mild cognitive impairment represents early-stage Alzheimer disease. Archives of Neurology,58(3), 397–405.
Mukherjee, A., Morales-Scheihing, D., Butler, P. C., & Soto, C. (2015). Type 2 diabetes as a protein misfolding disease. Trends in Molecular Medicine,21(7), 439–449. https://doi.org/10.1016/j.molmed.2015.04.005.
Mukherjee, A., Morales-Scheihing, D., Salvadores, N., Moreno-Gonzalez, I., Gonzalez, C., Taylor-Presse, K., et al. (2017). Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism. Journal of Experimental Medicine,214(9), 2591–2610. https://doi.org/10.1084/jem.20161134.
Mullard, A. (2019). Pioneering antisense drug heads into pivotal trials for Huntington disease. Nature Reviews Drug Discovery,18(3), 161–163. https://doi.org/10.1038/d41573-019-00018-7.
Muller, M., Jakel, L., Bruinsma, I. B., Claassen, J. A., Kuiperij, H. B., & Verbeek, M. M. (2016a). MicroRNA-29a is a candidate biomarker for Alzheimer’s disease in cell-free cerebrospinal fluid. Molecular Neurobiology,53(5), 2894–2899. https://doi.org/10.1007/s12035-015-9156-8.
Muller, M., Kuiperij, H. B., Claassen, J. A., Kusters, B., & Verbeek, M. M. (2014). MicroRNAs in Alzheimer’s disease: Differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiology of Aging,35(1), 152–158. https://doi.org/10.1016/j.neurobiolaging.2013.07.005.
Muller, M., Kuiperij, H. B., Versleijen, A. A., Chiasserini, D., Farotti, L., Baschieri, F., et al. (2016b). Validation of microRNAs in cerebrospinal fluid as biomarkers for different forms of dementia in a multicenter study. Journal of Alzheimers Disease,52(4), 1321–1333. https://doi.org/10.3233/JAD-160038.
Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., et al. (2011). Alzheimer’s disease is not “brain aging”: Neuropathological, genetic, and epidemiological human studies. Acta Neuropathologica,121(5), 571–587. https://doi.org/10.1007/s00401-011-0826-y.
Nelson, P. T., & Keller, J. N. (2007). RNA in brain disease: No longer just “the messenger in the middle”. Journal of Neuropathology and Experimental Neurology,66(6), 461–468. https://doi.org/10.1097/01.jnen.0000240474.27791.f3.
Nelson, P., Kiriakidou, M., Sharma, A., Maniataki, E., & Mourelatos, Z. (2003). The microRNA world: Small is mighty. Trends in Biochemical Sciences,28(10), 534–540. https://doi.org/10.1016/j.tibs.2003.08.005.
Nicolas, G., Wallon, D., Goupil, C., Richard, A. C., Pottier, C., Dorval, V., et al. (2016). Mutation in the 3′untranslated region of APP as a genetic determinant of cerebral amyloid angiopathy. European Journal of Human Genetics,24(1), 92–98. https://doi.org/10.1038/ejhg.2015.61.
Nixon, R. A. (2013). The role of autophagy in neurodegenerative disease. Nature Medicine,19(8), 983–997. https://doi.org/10.1038/nm.3232.
Nunez-Iglesias, J., Liu, C. C., Morgan, T. E., Finch, C. E., & Zhou, X. J. (2010). Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer’s disease cortex reveals altered miRNA regulation. PLoS ONE,5(2), e8898. https://doi.org/10.1371/journal.pone.0008898.
Patel, N., Hoang, D., Miller, N., Ansaloni, S., Huang, Q., Rogers, J. T., et al. (2008). MicroRNAs can regulate human APP levels. Molecular Neurodegeneration,3, 10. https://doi.org/10.1186/1750-1326-3-10.
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017). ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Frontiers in Aging Neuroscience,9, 68. https://doi.org/10.3389/fnagi.2017.00068.
Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., et al. (2013). Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology,80(11), 1048–1056. https://doi.org/10.1212/WNL.0b013e3182872830.
Price, J. L., Davis, P. B., Morris, J. C., & White, D. L. (1991). The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiology of Aging,12(4), 295–312.
Prusiner, S. B. (1982). Novel proteinaceous infectious particles cause scrapie. Science,216(4542), 136–144.
Prusiner, S. B. (1998). Prions. Proceedings of the National Academy of Sciences,95(23), 13363–13383.
Rabinovici, G. D., Jagust, W. J., Furst, A. J., Ogar, J. M., Racine, C. A., Mormino, E. C., et al. (2008). Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Annals of Neurology,64(4), 388–401. https://doi.org/10.1002/ana.21451.
Reddy, P. H., Tripathi, R., Troung, Q., Tirumala, K., Reddy, T. P., Anekonda, V., et al. (2012). Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: Implications to mitochondria-targeted antioxidant therapeutics. Biochimica et Biophysica Acta,1822(5), 639–649. https://doi.org/10.1016/j.bbadis.2011.10.011.
Revesz, T., Holton, J. L., Lashley, T., Plant, G., Rostagno, A., Ghiso, J., et al. (2002). Sporadic and familial cerebral amyloid angiopathies. Brain Pathology,12(3), 343–357.
Riancho, J., Vazquez-Higuera, J. L., Pozueta, A., Lage, C., Kazimierczak, M., Bravo, M., et al. (2017). MicroRNA profile in patients with Alzheimer’s disease: Analysis of miR-9-5p and miR-598 in raw and exosome enriched cerebrospinal fluid samples. Journal of Alzheimers Disease,57(2), 483–491. https://doi.org/10.3233/JAD-161179.
Richard, B. C., Kurdakova, A., Baches, S., Bayer, T. A., Weggen, S., & Wirths, O. (2015). Gene dosage dependent aggravation of the neurological phenotype in the 5XFAD mouse model of alzheimer’s disease. Journal of Alzheimers Disease,45(4), 1223–1236. https://doi.org/10.3233/JAD-143120.
Richards, J. G., Higgins, G. A., Ouagazzal, A. M., Ozmen, L., Kew, J. N., Bohrmann, B., et al. (2003). PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. Journal of Neuroscience,23(26), 8989–9003.
Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Sr., Rieck, J. R., Hebrank, A. C., Diaz-Arrastia, R., et al. (2012). β-Amyloid burden in healthy aging: Regional distribution and cognitive consequences. Neurology,78(6), 387–395. https://doi.org/10.1212/WNL.0b013e318245d295.
Rowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., et al. (2013). Predicting Alzheimer disease with beta-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Annals of Neurology,74(6), 905–913. https://doi.org/10.1002/ana.24040.
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., et al. (2010). Amyloid imaging results from the Australian imaging, biomarkers and lifestyle (AIBL) study of aging. Neurobiology of Aging,31(8), 1275–1283. https://doi.org/10.1016/j.neurobiolaging.2010.04.007.
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., et al. (2007). Imaging β-amyloid burden in aging and dementia. Neurology,68(20), 1718–1725. https://doi.org/10.1212/01.wnl.0000261919.22630.ea.
Rubinsztein, D. C., Codogno, P., & Levine, B. (2012). Autophagy modulation as a potential therapeutic target for diverse diseases. Nature Reviews Drug Discovery,11(9), 709–730. https://doi.org/10.1038/nrd3802.
Salta, E., Sierksma, A., Vanden Eynden, E., & De Strooper, B. (2016). miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer’s brain. EMBO Molecular Medicine,8(9), 1005–1018. https://doi.org/10.15252/emmm.201606520.
Sarazin, M., de Souza, L. C., Lehericy, S., & Dubois, B. (2012). Clinical and research diagnostic criteria for Alzheimer’s disease. Neuroimaging Clinics N Am. https://doi.org/10.1016/j.nic.2011.11.004.
Satoh, J., Kino, Y., & Niida, S. (2015). MicroRNA-Seq data analysis pipeline to identify blood biomarkers for alzheimer’s disease from public data. Biomarker Insights,10, 21–31. https://doi.org/10.4137/BMI.S25132.
Schipper, H. M., Maes, O. C., Chertkow, H. M., & Wang, E. (2007). MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regulation and Systems Biology,1, 263–274.
Schonrock, N., & Gotz, J. (2012). Decoding the non-coding RNAs in Alzheimer’s disease. Cellular and Molecular Life Sciences,69(21), 3543–3559. https://doi.org/10.1007/s00018-012-1125-z.
Schonrock, N., Ke, Y. D., Humphreys, D., Staufenbiel, M., Ittner, L. M., Preiss, T., et al. (2010). Neuronal microRNA deregulation in response to Alzheimer’s disease amyloid-beta. PLoS ONE,5(6), e11070. https://doi.org/10.1371/journal.pone.0011070.
Schratt, G. (2009). microRNAs at the synapse. Nature Reviews Neuroscience,10(12), 842–849. https://doi.org/10.1038/nrn2763.
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine,1(1), a006189. https://doi.org/10.1101/cshperspect.a006189.
Shan, G., Li, Y., Zhang, J., Li, W., Szulwach, K. E., Duan, R., et al. (2008). A small molecule enhances RNA interference and promotes microRNA processing. Nature Biotechnology,26(8), 933–940. https://doi.org/10.1038/nbt.1481.
Shioya, M., Obayashi, S., Tabunoki, H., Arima, K., Saito, Y., Ishida, T., et al. (2010). Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathology and Applied Neurobiology,36(4), 320–330. https://doi.org/10.1111/j.1365-2990.2010.01076.x.
Siegel, G., Obernosterer, G., Fiore, R., Oehmen, M., Bicker, S., Christensen, M., et al. (2009). A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nature Cell Biology,11(6), 705–716. https://doi.org/10.1038/ncb1876.
Sierksma, A., Lu, A., Salta, E., Vanden Eynden, E., Callaerts-Vegh, Z., D’Hooge, R., et al. (2018). Deregulation of neuronal miRNAs induced by amyloid-beta or TAU pathology. Molecular Neurodegeneration,13(1), 54. https://doi.org/10.1186/s13024-018-0285-1.
Simonson, B., & Das, S. (2015). MicroRNA therapeutics: The next magic bullet? Mini Reviews in Medicinal Chemistry.,15(6), 467–474.
Simpson, R. J., Lim, J. W., Moritz, R. L., & Mathivanan, S. (2009). Exosomes: Proteomic insights and diagnostic potential. Expert Review of Proteomics,6(3), 267–283. https://doi.org/10.1586/epr.09.17.
Singer, O., Marr, R. A., Rockenstein, E., Crews, L., Coufal, N. G., Gage, F. H., et al. (2005). Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nature Neuroscience,8(10), 1343–1349. https://doi.org/10.1038/nn1531.
Smith, P. Y., Delay, C., Girard, J., Papon, M. A., Planel, E., Sergeant, N., et al. (2011). MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Human Molecular Genetics,20(20), 4016–4024. https://doi.org/10.1093/hmg/ddr330.
Smith, P. Y., Hernandez-Rapp, J., Jolivette, F., Lecours, C., Bisht, K., Goupil, C., et al. (2015). miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Human Molecular Genetics,24(23), 6721–6735. https://doi.org/10.1093/hmg/ddv377.
Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Reviews Neuroscience,4(1), 49–60. https://doi.org/10.1038/nrn1007.
Soto, C., Estrada, L., & Castilla, J. (2006). Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends in Biochemical Sciences,31(3), 150–155. https://doi.org/10.1016/j.tibs.2006.01.002.
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement,7(3), 280–292. https://doi.org/10.1016/j.jalz.2011.03.003.
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K. H., Mistl, C., Rothacher, S., et al. (1997). Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proceedings of the National Academy of Sciences USA,94(24), 13287–13292.
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., et al. (2019). Vascular dysfunction-the disregarded partner of Alzheimer’s disease. Alzheimers Dement,15(1), 158–167. https://doi.org/10.1016/j.jalz.2018.07.222.
Tan, L., Yu, J. T., Liu, Q. Y., Tan, M. S., Zhang, W., Hu, N., et al. (2014). Circulating miR-125b as a biomarker of Alzheimer’s disease. Journal of the Neurological Sciences,336(1–2), 52–56. https://doi.org/10.1016/j.jns.2013.10.002.
Terrinoni, A., Calabrese, C., Basso, D., Aita, A., Caporali, S., Plebani, M., et al. (2018). The circulating miRNAs as diagnostic and prognostic markers. Clinical Chemistry and Laboratory Medicine. https://doi.org/10.1515/cclm-2018-0838.
Tiribuzi, R., Crispoltoni, L., Porcellati, S., Di Lullo, M., Florenzano, F., Pirro, M., et al. (2014). miR128 up-regulation correlates with impaired amyloid beta(1-42) degradation in monocytes from patients with sporadic Alzheimer’s disease. Neurobiology of Aging,35(2), 345–356. https://doi.org/10.1016/j.neurobiolaging.2013.08.003.
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., et al. (2014). Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathologica Communications,2, 26. https://doi.org/10.1186/2051-5960-2-26.
Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., et al. (2010). A mouse model of amyloid beta oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. Journal of Neuroscience,30(14), 4845–4856. https://doi.org/10.1523/JNEUROSCI.5825-09.2010.
Toyama, K., Spin, J. M., & Tsao, P. S. (2017). Role of microRNAs on blood brain barrier dysfunction in vascular cognitive impairment. Current Drug Delivery,14(6), 744–757. https://doi.org/10.2174/1567201813666160830124627.
Tsoi, H., Lau, T. C., Tsang, S. Y., Lau, K. F., & Chan, H. Y. (2012). CAG expansion induces nucleolar stress in polyglutamine diseases. Proceedings of the National Academy of Sciences USA,109(33), 13428–13433. https://doi.org/10.1073/pnas.1204089109.
Uversky, V. N. (2007). Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. Journal of Neurochemistry,103(1), 17–37. https://doi.org/10.1111/j.1471-4159.2007.04764.x.
van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., et al. (2013a). Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology,81(16), 1409–1416. https://doi.org/10.1212/WNL.0b013e3182a8418b.
van Harten, A. C., Visser, P. J., Pijnenburg, Y. A., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., et al. (2013b). Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement,9(5), 481–487. https://doi.org/10.1016/j.jalz.2012.08.004.
Vilardo, E., Barbato, C., Ciotti, M., Cogoni, C., & Ruberti, F. (2010). MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. Journal of Biological Chemistry,285(24), 18344–18351. https://doi.org/10.1074/jbc.M110.112664.
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., et al. (2013). Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol,12(4), 357–367. https://doi.org/10.1016/S1474-4422(13)70044-9.
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015). Tau imaging: Early progress and future directions. Lancet Neurology,14(1), 114–124. https://doi.org/10.1016/S1474-4422(14)70252-2.
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L. O., Freund-Levi, Y., et al. (2009). Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurology,8(7), 619–627. https://doi.org/10.1016/S1474-4422(09)70139-5.
Walsh, D. M., & Selkoe, D. J. (2007). A beta oligomers - a decade of discovery. Journal of Neurochemistry,101(5), 1172–1184. https://doi.org/10.1111/j.1471-4159.2006.04426.x.
Wang, T., Chen, K., Li, H., Dong, S., Su, N., Liu, Y., et al. (2015). The feasibility of utilizing plasma MiRNA107 and BACE1 messenger RNA gene expression for clinical diagnosis of amnestic mild cognitive impairment. Journal of Clinical Psychiatry,76(2), 135–141. https://doi.org/10.4088/JCP.13m08812.
Wang, W. X., Huang, Q., Hu, Y., Stromberg, A. J., & Nelson, P. T. (2011). Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: White matter versus gray matter. Acta Neuropathologica,121(2), 193–205. https://doi.org/10.1007/s00401-010-0756-0.
Wang, G., Huang, Y., Wang, L. L., Zhang, Y. F., Xu, J., Zhou, Y., et al. (2016). MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer’s disease. Scientific Reports,6, 26697. https://doi.org/10.1038/srep26697.
Wang, X., Liu, D., Huang, H. Z., Wang, Z. H., Hou, T. Y., Yang, X., et al. (2018). A novel MicroRNA-124/PTPN1 signal pathway mediates synaptic and memory deficits in Alzheimer’s disease. Biological Psychiatry,83(5), 395–405. https://doi.org/10.1016/j.biopsych.2017.07.023.
Wang, W. X., Rajeev, B. W., Stromberg, A. J., Ren, N., Tang, G., Huang, Q., et al. (2008). The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. Journal of Neuroscience,28(5), 1213–1223. https://doi.org/10.1523/JNEUROSCI.5065-07.2008.
Westermark, P., Andersson, A., & Westermark, G. T. (2011). Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological Reviews,91(3), 795–826. https://doi.org/10.1152/physrev.00042.2009.
Williams, A., Sarkar, S., Cuddon, P., Ttofi, E. K., Saiki, S., Siddiqi, F. H., et al. (2008). Novel targets for Huntington’s disease in an mTOR-independent autophagy pathway. Nature Chemical Biology,4(5), 295–305. https://doi.org/10.1038/nchembio.79.
Wirth, M., Madison, C. M., Rabinovici, G. D., Oh, H., Landau, S. M., & Jagust, W. J. (2013). Alzheimer’s disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. Journal of Neuroscience,33(13), 5553–5563. https://doi.org/10.1523/JNEUROSCI.4409-12.2013.
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L., et al. (2015). A genetic cause of Alzheimer disease: Mechanistic insights from Down syndrome. Nature Reviews Neuroscience,16(9), 564–574. https://doi.org/10.1038/nrn3983.
Wolfe, M. S. (2014). Targeting mRNA for Alzheimer’s and related dementias. Scientifica (Cairo),2014, 757549. https://doi.org/10.1155/2014/757549.
Wu, B. W., Wu, M. S., & Guo, J. D. (2018). Effects of microRNA-10a on synapse remodeling in hippocampal neurons and neuronal cell proliferation and apoptosis through the BDNF-TrkB signaling pathway in a rat model of Alzheimer’s disease. Journal of Cellular Physiology,233(7), 5281–5292. https://doi.org/10.1002/jcp.26328.
Wu, Y., Xu, J., Xu, J., Cheng, J., Jiao, D., Zhou, C., et al. (2017). Lower serum levels of miR-29c-3p and miR-19b-3p as biomarkers for Alzheimer’s disease. Tohoku Journal of Experimental Medicine,242(2), 129–136. https://doi.org/10.1620/tjem.242.129.
Xu, Y., Chen, P., Wang, X., Yao, J., & Zhuang, S. (2018). miR-34a deficiency in APP/PS1 mice promotes cognitive function by increasing synaptic plasticity via AMPA and NMDA receptors. Neuroscience Letters,670, 94–104. https://doi.org/10.1016/j.neulet.2018.01.045.
Xu, N., Li, A. D., Ji, L. L., Ye, Y., Wang, Z. Y., & Tong, L. (2019). miR-132 regulates the expression of synaptic proteins in APP/PS1 transgenic mice through C1q. European Journal of Histochemistry,63(2), 458. https://doi.org/10.4081/ejh.2019.3008.
Yang, L. B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X. L., et al. (2003). Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nature Medicine,9(1), 3–4. https://doi.org/10.1038/nm0103-3.
Yang, G., Song, Y., Zhou, X., Deng, Y., Liu, T., Weng, G., et al. (2015). MicroRNA-29c targets beta-site amyloid precursor protein-cleaving enzyme 1 and has a neuroprotective role in vitro and in vivo. Molecular Medicine Reports,12(2), 3081–3088. https://doi.org/10.3892/mmr.2015.3728.
Yao, J., Hennessey, T., Flynt, A., Lai, E., Beal, M. F., & Lin, M. T. (2010). MicroRNA-related cofilin abnormality in Alzheimer’s disease. PLoS ONE,5(12), e15546. https://doi.org/10.1371/journal.pone.0015546.
Yilmaz, S. G., Erdal, M. E., Ozge, A. A., & Sungur, M. A. (2016). Can peripheral MicroRNA expression data serve as epigenomic (upstream) biomarkers of Alzheimer’s disease? OMICS: A Journal of Integrative Biology,20(8), 456–461. https://doi.org/10.1089/omi.2016.0099.
Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., et al. (2014). A data-driven model of biomarker changes in sporadic Alzheimer’s disease. Brain,137(Pt 9), 2564–2577. https://doi.org/10.1093/brain/awu176.
Zhang, B., Chen, C. F., Wang, A. H., & Lin, Q. F. (2015). MiR-16 regulates cell death in Alzheimer’s disease by targeting amyloid precursor protein. Eur Rev Med Pharmacol Sci,19(21), 4020–4027.
Zhang, Y., Li, Q., Liu, C., Gao, S., Ping, H., Wang, J., et al. (2016a). MiR-214-3p attenuates cognition defects via the inhibition of autophagy in SAMP8 mouse model of sporadic Alzheimer’s disease. Neurotoxicology,56, 139–149. https://doi.org/10.1016/j.neuro.2016.07.004.
Zhang, Y., Xing, H., Guo, S., Zheng, Z., Wang, H., & Xu, D. (2016b). MicroRNA-135b has a neuroprotective role via targeting of beta-site APP-cleaving enzyme 1. Experimental and Therapeutic Medicine,12(2), 809–814. https://doi.org/10.3892/etm.2016.3366.
Zhang, J. A., Zhou, B. R., Xu, Y., Chen, X., Liu, J., Gozali, M., et al. (2016c). MiR-23a-depressed autophagy is a participant in PUVA- and UVB-induced premature senescence. Oncotarget,7(25), 37420–37435. https://doi.org/10.18632/oncotarget.9357.
Zhao, Y., Zhao, R., Wu, J., Wang, Q., Pang, K., Shi, Q., et al. (2018). Melatonin protects against Abeta-induced neurotoxicity in primary neurons via miR-132/PTEN/AKT/FOXO3a pathway. BioFactors,44(6), 609–618. https://doi.org/10.1002/biof.1411.
Zheng, H., Jiang, M., Trumbauer, M. E., Sirinathsinghji, D. J., Hopkins, R., Smith, D. W., et al. (1995). beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell,81(4), 525–531.
Zhou, Y., Wang, Z. F., Li, W., Hong, H., Chen, J., Tian, Y., et al. (2018). Protective effects of microRNA-330 on amyloid beta-protein production, oxidative stress, and mitochondrial dysfunction in Alzheimer’s disease by targeting VAV1 via the MAPK signaling pathway. Journal of Cellular Biochemistry,119(7), 5437–5448. https://doi.org/10.1002/jcb.26700.
Zhu, H. C., Wang, L. M., Wang, M., Song, B., Tan, S., Teng, J. F., et al. (2012). MicroRNA-195 downregulates Alzheimer’s disease amyloid-beta production by targeting BACE1. Brain Research Bulletin,88(6), 596–601. https://doi.org/10.1016/j.brainresbull.2012.05.018.
Zipfel, G. J., Han, H., Ford, A. L., & Lee, J. M. (2009). Cerebral amyloid angiopathy: Progressive disruption of the neurovascular unit. Stroke,40(3 Suppl), S16–S19. https://doi.org/10.1161/STROKEAHA.108.533174.
Zwan, M. D., Bouwman, F. H., Konijnenberg, E., van der Flier, W. M., Lammertsma, A. A., Verhey, F. R., et al. (2017). Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia. Alzheimers Research Therapy,9(1), 2. https://doi.org/10.1186/s13195-016-0228-4.
Acknowledgements
This work was supported by NIH/NINDS NS094543 and NS096493 (to LDM).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Weldon Furr, J., Morales-Scheihing, D., Manwani, B. et al. Cerebral Amyloid Angiopathy, Alzheimer’s Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets. Neuromol Med 21, 369–390 (2019). https://doi.org/10.1007/s12017-019-08568-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-019-08568-0